Daniel E. Haggstrom

Daniel E. Haggstrom

Hematology | Oncology

1021 Morehead Medical Drive
Building 2, Suite 30500
Charlotte, NC 28204

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.

Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Oncology

Published: May 31, 2024

Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Journal: JCO precision oncology

Published: November 01, 2020

Identifying potentially inappropriate medication (PIM) use in geriatric oncology.

Identifying potentially inappropriate medication (PIM) use in geriatric oncology.

Journal: Journal of geriatric oncology

Published: December 17, 2019

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.

Journal: Frontiers in oncology

Published: March 29, 2018

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 22, 2017

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).

Journal: Translational lung cancer research

Published: December 03, 2015

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Journal: The New England journal of medicine

Published: April 30, 2015

New targets and new mechanisms in lung cancer.

New targets and new mechanisms in lung cancer.

Journal: Oncology (Williston Park, N.Y.)

Published: May 15, 2013

Showing 1-8 of 8

Last Updated: 09/26/2026